Evidence map›Paper›PMID 30940115›Full record

ArticleBMC nephrology2019

Higher serum uric acid level is inversely associated with renal function assessed by cystatin C in a Japanese general population without chronic kidney disease: the KOBE study.

Sachimi Kubo, Yoko Nishida, Yoshimi Kubota, Aya Higashiyama, Daisuke Sugiyama, Takumi Hirata, Naomi Miyamatsu, Ayumi Tanabe, Aya Hirata, Yukako Tatsumi and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Sachimi KuboCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan. kubo@fbri.org.
Yoko NishidaCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Yoshimi KubotaCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Aya HigashiyamaCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Daisuke SugiyamaCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Takumi HirataCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Naomi MiyamatsuCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Ayumi TanabeCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Aya HirataCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Yukako TatsumiCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Aya KadotaCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Kazuyo KuwabaraCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Tomofumi NishikawaCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Yoshihiro MiyamotoCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Tomonori OkamuraCohort Study Team, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima Minamimachi, Chuo-ku, Hyogo, 650-0047, Japan.
Foundation for Biomedical Research and Innovation · JPKeio University · JPShiga University of Medical Science · JPKyoto Koka Women's University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough several epidemiological studies have suggested that high serum uric acid (SUA) levels are related to a decline in kidney function, only a few studies have investigated using cystatin C to calculate estimated glomerular filtration rate (eGFR). We aimed to clarify the relationship between SUA levels and kidney function assessed by cystatin C in a Japanese general community population without chronic kidney disease (CKD).

methodsWe conducted a community-based cross-sectional study that included 1086 healthy participants, aged 40-74 years, without CKD and not undergoing treatment of hyperuricemia, who had participated in the baseline survey of the Kobe Orthopedic and Biomedical Epidemiological (KOBE) study. The preconditions for participation in this study were no past histories of cardiovascular disease or cancer, and not undergoing treatment for diabetes, hypertension, or dyslipidemia. We classified the participants into quartiles stratified by sex according to their SUA level and then examined the relationship with eGFR. The odds ratios for having a low eGFR, defined as the lowest quartile of eGFR (i.e., ≤78.4 mL/min/1. 73m

resultsMultivariable-adjusted means of eGFR showed a graded decrease in higher SUA quartiles (men, Q1 90.5, Q2 88.0, Q3 83.5, and Q4 82.0; women, Q1 95.7, Q2 91.3, Q3 89.2, and Q4 86.7). In addition, the multivariable-adjusted odds ratios for having a lower eGFR (95% confidence interval) for each SUA quartile compared with Q1 was Q2 2.29 (0.98, 5.35), Q3 4.94 (2.04, 11.97), and Q4 8.01 (3.20, 20.04) for men, and was Q2 2.20 (1.12, 4.32), Q3 2.68 (1.39, 5.20), and Q4 4.96 (2.62, 9.41) for women.

conclusionsThere was a graded inverse relationship between mild elevations in SUA levels and eGFR assessed by cystatin C in an apparently healthy Japanese population without CKD. This association was similar in both men and women.

Indexed as

Glomerular Filtration RateKidney Function TestsAlcohol DrinkingBlood PressureBody Mass IndexCross-Sectional StudiesCystatin CFemaleGlycated HemoglobinHealthy VolunteersHumansJapanMaleMiddle AgedPublic Health SurveillanceSmokingCystatin CGlycated HemoglobinUric AcidA community-based studyChronic kidney diseaseCystatin CSerum uric acid

Identifiers

PMID30940115
PMCPMC6446294
OpenAlexW2939127626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.